SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1.
Antibody
COVID19
Neutralization
RBD
SARS-CoV-2
VOC
Vaccine
Variant
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
24 09 2021
24 09 2021
Historique:
received:
25
06
2021
revised:
19
08
2021
accepted:
23
08
2021
pubmed:
6
9
2021
medline:
24
9
2021
entrez:
5
9
2021
Statut:
ppublish
Résumé
SARS-CoV-2 is the etiological agent of COVID19. There are currently several licensed vaccines approved for human use and most of them target the spike protein in the virion envelope to induce protective immunity. Recently, variants that spread more quickly have emerged. There is evidence that some of these variants are less sensitive to neutralization in vitro, but it is not clear whether they can evade vaccine induced protection. In this study, we tested SARS-CoV-2 spike RBD as a vaccine antigen and explored the effect of formulation with Alum/MPLA or AddaS03 adjuvants. Our results show that RBD induces high titers of neutralizing antibodies and activates strong cellular immune responses. There is also significant cross-neutralization of variants B.1.1.7 and B.1.351 and to a lesser extent, SARS-CoV-1. These results indicate that recombinant RBD can be a viable candidate as a stand-alone vaccine or as a booster shot to diversify our strategy for COVID19 protection.
Identifiants
pubmed: 34481699
pii: S0264-410X(21)01129-4
doi: 10.1016/j.vaccine.2021.08.081
pmc: PMC8387217
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Spike Glycoprotein, Coronavirus
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5769-5779Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Nature. 2020 Aug;584(7821):450-456
pubmed: 32698192
Clin Transl Immunology. 2021 Mar 07;10(3):e1260
pubmed: 33732459
Lancet. 2021 Apr 17;397(10283):1459-1469
pubmed: 33844963
Nat Med. 2021 May;27(5):917-924
pubmed: 33772244
Cell. 2020 Sep 3;182(5):1295-1310.e20
pubmed: 32841599
Cell Host Microbe. 2021 Jan 13;29(1):44-57.e9
pubmed: 33259788
Nature. 2020 Oct;586(7830):516-527
pubmed: 32967006
JAMA. 2021 Feb 23;325(8):780-781
pubmed: 33475702
Signal Transduct Target Ther. 2020 Sep 22;5(1):212
pubmed: 32963228
N Engl J Med. 2021 Jun 3;384(22):2092-2101
pubmed: 33835769
Vaccine. 2019 May 21;37(23):3006-3021
pubmed: 31031030
N Engl J Med. 2021 Jun 3;384(22):2124-2130
pubmed: 33835768
Front Immunol. 2018 May 31;9:1194
pubmed: 29904384
Cell. 2021 Apr 29;184(9):2332-2347.e16
pubmed: 33761326
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
J Appl Toxicol. 2015 Dec;35(12):1564-76
pubmed: 25727696
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Nature. 2011 Apr 28;472(7344):481-5
pubmed: 21478870
PLoS Pathog. 2021 Jan 21;17(1):e1009233
pubmed: 33476327
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
Nat Commun. 2021 Mar 3;12(1):1403
pubmed: 33658497
Sci Immunol. 2020 Jun 19;5(48):
pubmed: 32561559
Nat Med. 2021 Jan;27(1):106-114
pubmed: 33288923
J Exp Med. 2020 Nov 2;217(11):
pubmed: 32692348
Nature. 2021 May;593(7857):142-146
pubmed: 33780970
Nature. 2020 Jul;583(7815):290-295
pubmed: 32422645
Mol Cell. 2020 May 21;78(4):779-784.e5
pubmed: 32362314
J Virol. 2016 Dec 16;91(1):
pubmed: 27795422
Nature. 2020 Oct;586(7830):594-599
pubmed: 32998157
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
MMWR Morb Mortal Wkly Rep. 2021 Jan 15;70(2):46-51
pubmed: 33444297
Nature. 2021 Mar;591(7849):293-299
pubmed: 33494095
Science. 2021 Feb 12;371(6530):735-741
pubmed: 33436524
J Virol. 2012 Aug;86(15):7760-70
pubmed: 22593152
Nat Med. 2020 Apr;26(4):450-452
pubmed: 32284615
J Mol Biol. 2020 May 1;432(10):3309-3325
pubmed: 32320687
PLoS Pathog. 2017 Nov 30;13(11):e1006698
pubmed: 29190287
Nature. 2020 Oct;586(7830):572-577
pubmed: 32726802
Nature. 2021 Jun;594(7862):253-258
pubmed: 33873199
Cell Host Microbe. 2021 Mar 10;29(3):463-476.e6
pubmed: 33592168
Cell. 2020 Dec 10;183(6):1735
pubmed: 33306958
Science. 2021 Mar 12;371(6534):1152-1153
pubmed: 33514629
Nature. 2021 Sep;597(7874):97-102
pubmed: 34261126
Traffic. 2016 Jun;17(6):593-614
pubmed: 26935856
Nat Med. 2021 Apr;27(4):620-621
pubmed: 33558724
Vaccine. 2020 Nov 3;38(47):7533-7541
pubmed: 33039209
Nature. 2021 Apr;592(7855):616-622
pubmed: 33567448
Influenza Other Respir Viruses. 2011 Sep;5(5):299-305
pubmed: 21668694
Sci Rep. 2020 Oct 19;10(1):17698
pubmed: 33077899
Nat Commun. 2020 Mar 27;11(1):1620
pubmed: 32221306
Cell. 2020 Nov 12;183(4):1024-1042.e21
pubmed: 32991844
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Curr Opin Immunol. 2018 Aug;53:143-151
pubmed: 29775847
Methods Mol Biol. 2015;1282:1-23
pubmed: 25720466
J Am Geriatr Soc. 2021 Aug;69(8):2063-2069
pubmed: 33861873
PLoS Pathog. 2021 Mar 24;17(3):e1009392
pubmed: 33760889
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Nature. 2021 May;593(7857):130-135
pubmed: 33684923
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279